Skip to main content
Premium Trial:

Request an Annual Quote

DermTech, Dermpath Ink Marketing Partnership

NEW YORK (GenomeWeb) – DermTech, a private developer of gene expression-based tests for skin diseases, announced today that it has formed a sales and marketing collaboration with Dermpath Diagnostics.

Under the terms of the deal, Dermpath — a Quest Diagnostics-owned dermatopathology services provider — will provide specialty dermatology representatives in up to 10 regional territories across the US to help DermTech in marketing its Pigmented Lesion assay (PLA), which analyzes the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions.

Additional terms of the arrangement were not disclosed.

"This collaboration will significantly expand our ability to offer the PLA to dermatologists in the US," Sarah Dennison, vice president of marketing at DermTech, said in a statement. 

Michael Kramer, vice president of dermatopathology at Dermpath, added, "We are pleased to align with DermTech in offering their innovative PLA and to further our mission to provide comprehensive dermatopathology services to the medical community."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.